Video

Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

Author(s):

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia (ALL).

Patients with low lymphocyte counts after chemotherapy or allogeneic stem cell transplantation ​could benefit from off-the-shelf CAR T-cell products as collecting T cells can be challenging, says Park.

Moreover, patients may experience disease progression during the 3 to 4-week period of T-cell generation that may be mitigated by an off-the-shelf option, concludes Park.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD